Loading...
Please wait, while we are loading the content...
Similar Documents
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Marechal, R. A. Le Mackey, John R. Lai, Raymond Demetter, Pieter Peeters, Marc Polus, Marc Cass, Carol E. Young, James Salmon, Isabelle Deviére, Jacques Laethem, Jean-Luc Van |
| Copyright Year | 2009 |
| Abstract | PURPOSE Gemcitabine is a promising adjuvant treatment for patients with resected pancreatic adenocarcinoma and its use in combination with radiotherapy is under exploration. Human equilibrative nucleoside transporter 1 (hENT1) and human concentrative nucleoside transporter (hCNT) 1 and 3 are the major transporters responsible for 2',2'-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. The aim of this study was to determine patients' outcome according to the expression of hENT1 and hCNT3 in tumoral cells after postoperative gemcitabine-based chemoradiation regimen. EXPERIMENTAL DESIGN We studied tumor blocks from 45 pancreatic adenocarcinoma patients treated with gemcitabine-based chemoradiation after curative resection and assessed hENT1 and hCNT3 expression using immunohistochemistry. RESULTS When adjusted for the effects of lymph node ratio and tumor diameter, patients with high hENT1 expression had significantly longer disease-free survival and overall survival (OS) than patients with low expression, whereas high hCNT3 expression was only associated with longer OS. In a combined analysis, patients with two favorable prognostic factors (hENT1(high)/hCNT3(high) expression) had a longer survival (median OS, 94.8 months) than those having one (median OS, 18.7 months) or no (median OS, 12.2 months) favorable prognostic factor. CONCLUSIONS Pancreatic adenocarcinoma patients with a high expression of hENT1 and hCNT3 immunostaining have a significantly longer survival after adjuvant gemcitabine-based chemoradiation. These biomarkers deserve prospective evaluation in patients receiving gemcitabine-based adjuvant therapy. |
| File Format | PDF HTM / HTML |
| DOI | 10.1158/1078-0432.CCR-08-2080 |
| PubMed reference number | 19318496 |
| Journal | Medline |
| Volume Number | 15 |
| Issue Number | 8 |
| Alternate Webpage(s) | http://clincancerres.aacrjournals.org/content/clincanres/15/8/2913.full.pdf |
| Alternate Webpage(s) | https://doi.org/10.1158/1078-0432.CCR-08-2080 |
| Journal | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
